FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_			. ,													
Name and Address of Reporting Person* Crowley John F						2. Issuer Name <b>and</b> Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [ FOLD ]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
														Λ					·		
(1+)	(=	:4\	/8.4: al all a.\			O Data of Facilitat Tananation (Marth/Dank/Dank/								X	Officer below)	(give title		Other (s	specify		
(Last)		*	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2020								Chairman & CEO							
C/O AM	ICUS THE	RAPEUTICS, II	VC.		100	00/15/2020										Cildiffild	пос	CEO			
1 CEDAR BROOK DRIVE																					
,					<b>–</b> 4. i	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)													[1	Line)							
CRANB	URY N	J	08512											X	Form fi	iled by One	Repo	orting Perso	n		
					_									Form filed by More than One Reporting							
(City)	(0	tota)	(7in)												Person	1					
(City) (State) (Zip)																					
		Tab	le I - I	lon-Deri	ivativ	e Sec	curit	ies A	cquire	ed, D	isposed o	f, or B	enefic	ially	Owned						
1. Title of 9	Security (Ins	tr. 3)		2. Transac	tion						5. Amount of 6. Ownership 7. Nature										
				Date (Month/Da	y/Year)				Transaction Code (Instr.		Disposed Of	(D) (Instr.	3, 4 and	d 5) Securit Benefic					of Indirect Beneficial		
				(e		(Month/Day/Year)		y/Year)	8)					Own		ed Following			Ownership (Instr. 4)		
								Code	V	Amount	(A) or	Price		Reported Transaction(s)				(111501.4)			
									Coue	Ľ	Amount	(D)	riice		(Instr. 3 and 4)						
Common Stock 06/15/					2020	)20			M		20,000	A	<b>\$5.</b> .	13 92		,186		D			
Common Stock 06/15/2				2020	20		S <sup>(1)</sup>		20,000	D	\$10.88	8805 <sup>(2)</sup>		0,186		D					
Common Stock 06/15/20					1020	20		3. 7	Ш	20,000		Ψ10.00	5.0005		70,100		<u> </u>				
Common Stock 06/15/202				2020	20		F		163	D	\$ <del>11</del> .	\$11.14		900,023		D					
Common Stock														64,895		I	By Trust				
			Table I	L - Deriv	ative	Secu	ritic	es Acc	uired	l Die	posed of,	or Rei	neficia	lly O	wned						
			iabic								, convertil				wiicu						
1. Title of	2.	3. Transaction	3A. Dec	emed	4.		5. N	umber	6. Dat	e Exer	cisable and	7. Title a	nd Amou	ınt 8.	Price of	9. Number	of	10.	11. Nature		
Derivative Security	Conversion or Exercise	Date (Month/Day/Year)	Execut if any	ion Date,		ansaction de (Instr.				ation D		of Securities Underlying			erivative ecurity	derivative Securities		Ownership Form:	of Indirect Beneficial		
(Instr. 3)	Price of			/Day/Year)	8)	msu.	Securities		(WOTIL	прауг	rear)	Derivative Secu			nstr. 5)	Beneficially		Direct (D)	Ownership		
	Derivative Security						Acquired (A) or				(Instr. 3 and 4)					Owned Following		or Indirect (I) (Instr. 4)	(Instr. 4)		
	Occurry						Disposed								Reported		(1) (1113411 4)				
						of (D) (Instr. 3, 4 and 5)									Transaction(s) (Instr. 4)						
					<del>-  </del>					Amo		ınt		ĺ .							
												l	or	1							
									Date		Expiration	l	Numb	er							
					Code	٧	(A)	(D)		isable	Date	Title	Share	s							
Stock																			_		
Options (right to	\$5.13	06/15/2020			M			20,000	(	3)	01/03/2027	Common	20,0	00	\$0.00	102,48	5	D			
buy)												Juck									

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$10.60 to \$11.17 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. As of June 15, 2020, 81,286 options were fully vested and exercisable and 41,199 remained unvested from this individual 2017 grant.

In addition to the reported transactions, Mr. Crowley also has approximately 1.56 million options outstanding and exercisable at various strike prices.

/s/ Christian Formica, Attorney- 06/17/2020 in-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.